AbbVie

AbbVie’s mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas –immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on X, Facebook, Instagram, YouTube, LinkedIn and Tik Tok.

1 North Waukegan Road
North Chicago, IL 60064

Visit website

Stock Symbol: ABBV
Stock Exchange: NYSE

Together, we break through.

Our principles are at the Heart of our Company. Operating as one AbbVie team, we care deeply for our patients, their families, our employees, and our communities. We strive to always do the right thing, pursuing the highest standards in quality, compliance, safety, and performance. In everything we do, we invest and innovate relentlessly to tackle unmet needs, creating new medicines and healthcare approaches for a healthier world.

How we work with each other and achieve results matters. That’s why we’ve been honored to receive some of the most prestigious ratings and recognitions in the industry, including being named on more than 40 Great Place to Work and Top Employer lists and FORTUNE “100 Best Companies to Work For.”

Click here to learn more about our principles.

NEWS

BioMidwest

AbbVie Donates $100 Million to Ronald McDonald House Charities

Illinois-based AbbVie stepped up to the plate and delivered when it came to supporting the families of children battling serious illnesses who require extended hospitalization.

August 21, 2018

2 min read

Alex Keown

Business

Magnolia Neurosciences Launches with $31 Million

Magnolia Neurosciences Corporation, co-founded by Accelerator Life Science Partners and The University of Texas MD Anderson Cancer Center, launched with a $31 million Series A financing.

August 13, 2018

3 min read

Mark Terry

Artios Snags $84 Million to Advance DDR Cancer Treatments

Artios Pharma Limited, based in Cambridge, U.K., got a significant financial boost from Pfizer, AbbVie and Novartis through an $84 million (£65 million) Series B funding that will help advance its DNA Damage Response (DDR) programs for cancer treatments.

August 10, 2018

2 min read

Alex Keown

Business

From “Jeans to Genes”: Mark Emalfarb Thinks He Can Revolutionize Biopharma Manufacturing

Mark Emalfarb, founder, chairman and chief executive officer of Jupiter, Florida-based Dyadic International, believes he knows how to revolutionize biopharma manufacturing. Emalfarb took time out to talk to BioSpace about his company and its C1 technology platform.

August 6, 2018

5 min read

Mark Terry

Business

Skeptical Investors Should Take Another Look at AbbVie

Investors have been skeptical about AbbVie lately, particularly after last week’s second-quarter financial report. That doesn’t make all that much sense, given that the company reported net revenues of $8.278 billion for the quarter.

July 30, 2018

3 min read

Mark Terry

Business

Alector Closes $133 Million to Expand Alzheimer’s Programs

South San Francisco-based Alector closed on a Series E financing worth $133 million. The money will be used to advance the company’s clinical programs and expand its discovery platform.

July 25, 2018

3 min read

Mark Terry

Drug Development

AbbVie, Neurocrine Snag FDA Approval for Oral Endometriosis Treatment Elagolix

Shares of AbbVie are up slightly this morning after the company announced that it finally received regulatory approval for its endometriosis drug elagolix. The approval marks the first new approved oral treatment for endometriosis-associated pain in more than 10 years.

July 24, 2018

2 min read

Alex Keown

Business

AbbVie Strikes Deal With Mylan to Delay Humira Biosimilar Challenge

AbbVie continues to do what it can to protect its Humira-driven revenue stream. This morning the company inked an agreement to grant Mylan the rights to begin marketing its biosimilar to Humira in the United States in 2023.

July 17, 2018

2 min read

Alex Keown

Business

Dermavant Bags GSK Phase III-Ready Psoriasis Treatment in $330 Million Deal

Months after tapping GlaxoSmithKline dermatology division executive David Rubenstein as its new chief scientific officer, Vivek Ramaswamy’s Dermavant Sciences has returned to the pharma giant to acquire a Phase III-ready psoriasis treatment.

July 12, 2018

2 min read

Alex Keown

JOBS